Firm Record

AbbVie Inc. findings history

30 findings from 6 inspection documents published by regulators. Each row below says what its date means.

Health Canada 2022-06-13 ~ 2023-08-01 6 documents 30 findings

Areas cited

Other quality systemEquipment and facilityDeviation, CAPA, and investigationComplaint and recall handlingStability and storageTraining and personnelAseptic processing and sterility assuranceLaboratory and QC controlsContamination controlMaterial and supplier controlComputer system validation

Published inspection documents

2023-08-01 Health Canada 3 findingsOther quality system · Equipment and facility The traceability, legibility, documentation, formatting, and/or the accuracy of records was inadequate. 2023-07-18 Health Canada 6 findingsStability and storage · Equipment and facility · Complaint and recall handling · Deviation, CAPA, and investigation · Other quality system The stability program did not include batches of drugs that had been stored for extended periods of time before they were packaged. 2023-03-08 Health Canada 3 findingsTraining and personnel · Stability and storage · Other quality system The job descriptions for personnel, the authority given to personnel, and/or the delegation of duties was inadequate and/or undocumented. 2022-06-13 Health Canada 6 findingsAseptic processing and sterility assurance · Other quality system · Complaint and recall handling · Equipment and facility The company did not take precautions to minimize contamination during all processing prior to sterilization. 2022-06-13 Health Canada 4 findingsComputer system validation · Deviation, CAPA, and investigation · Other quality system · Laboratory and QC controls The calibration, inspection, and/or qualification of the equipment, including computerized systems, was inadequate. 2022-06-13 Health Canada 8 findingsMaterial and supplier control · Deviation, CAPA, and investigation · Equipment and facility · Other quality system · Contamination control The premises and/or the manufacturing process were inadequate for minimizing contamination of the drugs and/or materials during fabrication and/or packaging.

About this page

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

What is included. As of 2026-09-03, only documents that have a detail page (at least 3 findings) are listed. The company may have more documents; the full set is available in Company lookup below.

Companies are grouped by a normalised key, not the displayed name — “… Limited” and “… Ltd.” count as the same company. Translation and classification are automated and may differ in nuance from the source; the basis for judgement is always the regulator's published document.

Full history of AbbVie Inc. — including inspection classifications Browse by document Go to Findings search